Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAL056 Mesylate Phase I Study in Solid Tumors
NCT04686383Phase 1Completed
- Sponsor
- Calgent Biotechnology
- Start
- Dec 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of CAL056 mesylate in solid tumor (5 cohorts), sponsored by Calgent Biotechnology. Primary endpoints: Number of patients with adverse events (AEs), serious adverse events (SAEs), and treatment emergent adverse events (TEAEs) up to 1 year, Number of patients with AEs qualified as dose-limiting toxicities and 6 more. Started Dec 2020; status: completed.
02
Drugs
CAL056 mesylate
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04686383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04686383.